Literature DB >> 3427210

Ophthalmic bioequivalence of steroid/antibiotic combination formulations.

R D Schoenwald1, R G Harris, D Turner, W Knowles, D S Chien.   

Abstract

This study compared the relative ocular bioavailability in rabbits of the antibiotic/steroid combination of 0.3 per cent tobramycin and 0.1 per cent fluorometholone acetate to each of the two single-entity products. Two separate studies were conducted, one measuring fluorometholone acetate in cornea and aqueous humour through 240 min and the other measuring tobramycin in the cornea through 120 min. The results for fluorometholone acetate show that the combination product is 15 per cent higher in AUC for the cornea than the single-entity product (0.05 less than p less than 0.1). However, the combination product is only 4.4 per cent higher in AUC when aqueous humour levels are compared (N.S.). The single-entity fluorometholone acetate ointment yielded cornea and aqueous humour levels which were 20 per cent (p less than 0.01) and 6 per cent (N.S.) higher in AUC than the same tissues measured after topical instillation of the suspension. Statistical treatment of the data indicated that the suspension and ointment products, were bioequivalent with respect to fluorometholone acetate in aqueous humour, but not with respect to corneal concentrations. Tobramycin was measured in the cornea following instillation of either the single-entity solution or the combination suspension. Per cent bound (tobramycin to rabbit antibodies determined in vitro from the radioimmunoassay results) was used for statistical analyses of all group means and standard errors. The results indicated that the products were bioinequivalent.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3427210     DOI: 10.1002/bdd.2510080605

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  8 in total

Review 1.  Ocular drug delivery. Pharmacokinetic considerations.

Authors:  R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

2.  Formulation, in vitro dissolution, and ocular bioavailability of high- and low-melting phenylephrine oxazolidines.

Authors:  Y Qiu; J K Guillory; R D Schoenwald
Journal:  Pharm Res       Date:  1993-11       Impact factor: 4.200

3.  Ocular pharmacokinetics and pharmacodynamics of phenylephrine and phenylephrine oxazolidine in rabbit eyes.

Authors:  D S Chien; R D Schoenwald
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

4.  Prophylactic effectiveness of tobramycin-dexamethasone eye drops compared with tobramycin/vehicle eye drops in controlling post-surgical inflammation in cataract patients : prospective, randomised, double-masked, two-arm, parallel-group, placebo-controlled, multicentre study.

Authors:  Ricardo Notivol; Dina Amin; Anna Whitling; David Wells; Margaret Kennedy; Paul C Cockrum
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

5.  Thermosensitive hydrogel based on chitosan and its derivatives containing medicated nanoparticles for transcorneal administration of 5-fluorouracil.

Authors:  Angela Fabiano; Ranieri Bizzarri; Ylenia Zambito
Journal:  Int J Nanomedicine       Date:  2017-01-16

6.  Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38.

Authors:  Megan E Cavet; Shellise Glogowski; Ezra R Lowe; Eric Phillips
Journal:  J Ocul Pharmacol Ther       Date:  2019-03-23       Impact factor: 2.671

7.  Impact of Different Mucoadhesive Polymeric Nanoparticles Loaded in Thermosensitive Hydrogels on Transcorneal Administration of 5-Fluorouracil.

Authors:  Angela Fabiano; Anna Maria Piras; Lorenzo Guazzelli; Barbara Storti; Ranieri Bizzarri; Ylenia Zambito
Journal:  Pharmaceutics       Date:  2019-11-21       Impact factor: 6.321

8.  Thiolated Hydroxypropyl-β-cyclodextrin: A Potential Multifunctional Excipient for Ocular Drug Delivery.

Authors:  Brunella Grassiri; Patrick Knoll; Angela Fabiano; Anna Maria Piras; Ylenia Zambito; Andreas Bernkop-Schnürch
Journal:  Int J Mol Sci       Date:  2022-02-26       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.